Clinical Trials Logo

Melanoma (Skin) clinical trials

View clinical trials related to Melanoma (Skin).

Filter by:

NCT ID: NCT00002845 Active, not recruiting - Melanoma (Skin) Clinical Trials

Interleukin-2 in Treating Patients With Metastatic Melanoma

Start date: September 1995
Phase: Phase 2
Study type: Interventional

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. PURPOSE: Phase II trial to study the effectiveness of interleukin-2 in treating patients who have metastatic melanoma.

NCT ID: NCT00002817 Active, not recruiting - Melanoma (Skin) Clinical Trials

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Start date: April 1996
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Vaccines may make the body build an immune response to kill melanoma cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients with metastatic melanoma.

NCT ID: NCT00002786 Completed - Melanoma (Skin) Clinical Trials

Biological Therapy in Treating Patients With Metastatic Melanoma

Start date: October 1995
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I/II trial to study the effectiveness of biological therapy in treating patients who have metastatic melanoma.

NCT ID: NCT00002781 Active, not recruiting - Melanoma (Skin) Clinical Trials

Boron Neutron Capture Therapy in Treating Patients With Stage III Melanoma

Start date: April 1996
Phase: Phase 1
Study type: Interventional

RATIONALE: Boron neutron capture therapy may selectively kill tumor cells without harming normal tissue. PURPOSE: Phase I trial to study the effectiveness of boron neuron capture therapy in treating patients with stage III melanoma.

NCT ID: NCT00002767 Active, not recruiting - Melanoma (Skin) Clinical Trials

Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma

Start date: January 1996
Phase: Phase 3
Study type: Interventional

RATIONALE: Interferon alfa may interfere with the growth of cancer cells.Vaccines may make the body build an immune response to kill tumor cells. It is not yet known whether melanoma vaccine plus interferon alfa is more effective than interferon alfa alone in treating patients with metastatic melanoma. PURPOSE: Randomized phase III trial to compare the effectiveness of interferon alfa with or without vaccine therapy in treating patients with metastatic melanoma.

NCT ID: NCT00002763 Active, not recruiting - Melanoma (Skin) Clinical Trials

High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma

Start date: April 1996
Phase: Phase 3
Study type: Interventional

RATIONALE: Interferon alfa may interfere with the growth of cancer cells. It is not known whether giving high-dose or low-dose interferon alfa is more effective than no further therapy in treating patients with stage III melanoma. PURPOSE: Randomized phase III trial to compare the effectiveness of high- or low-dose interferon alfa with that of no further therapy following surgery in treating patients who have stage III melanoma.

NCT ID: NCT00002754 Completed - Metastatic Cancer Clinical Trials

Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors

Start date: February 1993
Phase: Phase 1
Study type: Interventional

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to determine the effectiveness of monoclonal antibody therapy in treating patients who have primary or metastatic melanoma or brain tumors.

NCT ID: NCT00002733 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Biological Therapy in Treating Patients With Metastatic Cancer

Start date: January 1996
Phase: Phase 2
Study type: Interventional

RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies, including interferon alfa, interleukin-2, and tumor infiltrating lymphocytes, may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of biological therapies, including interferon alfa, interleukin-2, and tumor infiltrating lymphocytes, in treating patients with metastatic cancer.

NCT ID: NCT00002669 Completed - Melanoma (Skin) Clinical Trials

Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Start date: June 1995
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of the cancer cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. It is not yet known which treatment regimen is more effective in treating melanoma. PURPOSE: Randomized phase II trial to compare the effectiveness of two regimens of combination chemotherapy plus interferon alfa and interleukin-2 in treating patients who have metastatic melanoma.

NCT ID: NCT00002535 Completed - Melanoma (Skin) Clinical Trials

Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma

Start date: July 1993
Phase: Phase 2
Study type: Interventional

RATIONALE: Biological therapies use different ways to stimulate the immune system and stop tumor cells from growing. Combining biological therapies with indomethacin and cyclophosphamide may kill more tumor cells. PURPOSE: Phase II trial to compare the effectiveness of indomethacin and biological therapy with or without cyclophosphamide in treating patients who have advanced melanoma that has not responded to previous therapy.